{"id":"W4387809682","doi":"10.1016/j.annonc.2023.10.011","title":"LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Seagen; Genentech; Hope Foundation; AstraZeneca; Breast Cancer Research Foundation; Pfizer; Bristol-Myers Squibb; Merck","keywords":"Medicine; Pembrolizumab; Oncology; Stage (stratigraphy); Adjuvant; Chemotherapy; Breast cancer; Adjuvant chemotherapy; Internal medicine; Gynecology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002083734,0.0008316427,0.002937242,0.0006968849,0.0002245236,0.00003853401,0.0009066396,0.0004623213,0.003849613],"category_scores_gemma":[0.0005224079,0.000615599,0.0005262626,0.001476959,0.0004736643,0.0002297792,0.0002572399,0.0009394621,0.00004006079],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004071836,"about_ca_system_score_gemma":0.002969789,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01676337,"about_ca_topic_score_gemma":0.003857993,"domain_scores_codex":[0.9928911,0.0007513157,0.001860721,0.001321723,0.001386168,0.001788989],"domain_scores_gemma":[0.9937915,0.001786581,0.001093632,0.001412402,0.001286891,0.0006289436],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3393856,0.01546082,0.008947152,0.0008369192,0.003623147,0.0009974134,0.007394823,0.0001195438,0.06729037,0.0000444345,0.1943876,0.3615122],"study_design_scores_gemma":[0.4152745,0.1229393,0.04287045,0.000659293,0.0007180333,0.0002835794,0.005686439,0.00143078,0.1235557,0.0001279531,0.2848973,0.001556638],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768841,0.001209723,0.00009652746,0.01152796,0.0006028009,0.006640688,0.002316653,0.0002336006,0.0004879293],"genre_scores_gemma":[0.9620383,0.01805997,0.0002997702,0.002193984,0.0005364348,0.002190471,0.0001997419,0.0002990597,0.0141823],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3599555,"threshold_uncertainty_score":0.9996296,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1272431833263286,"score_gpt":0.4865900282985598,"score_spread":0.3593468449722312,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}